Navigation Links
MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
Date:9/7/2010

MOUNTAIN VIEW, Calif., Sept. 7 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following healthcare conferences in September:

Morgan Stanley Global Healthcare Conference

Tuesday, September 14, at 11:30 a.m. ET in New York

Stifel Nicolaus 2010 Healthcare ConferenceWednesday, September 15, at 2:05 p.m. ET in Boston

UBS Global Life Sciences Conference

Tuesday, September 21, at 9:00 a.m. ET in New York

A live webcast of the events will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours following the presentation.

In addition, the Company will be presenting its LEVADEX™ orally inhaled migraine therapy Phase 3 data at the American Neurological Association's 135th Annual Meeting on Monday, September 13, at 1:00 p.m. in San Francisco.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com. CONTACTS:Nicole Foderaro WCG(415) 946-1058nfoderaro@wcgworld.com
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
2. Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
3. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
4. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
6. Pfizer to Acquire FoldRx Pharmaceuticals
7. Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China
8. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
9. Webcast Alert: Isis Pharmaceuticals Hosts Expert Panel Conference Call to Discuss Mipomersen Data Presented at the ESC Congress 2010
10. Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
11. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016   HighPoint Solutions today ... (NRG),s pharmacovigilance technology services division.  NRG is a ... an Oracle Argus Specialized partner, providing drug safety ... companies. --> --> ... sciences capabilities and provides a global scale and ...
(Date:2/8/2016)... part of a major growth and expansion initiative, Dune Medical ... Chmura as President of Dune Inc., its U.S. division. ... experience in the medical device space will play a large ... --> --> In her new ... and operational functions in the U.S. She is tasked with ...
(Date:2/8/2016)... Feb. 8, 2016 Velano Vascular, a medical ... hospitalized patients and their practitioners, announced today that the ... Velano will use the proceeds from this financing, an ... in January 2015, to support the development and commercialization ... pediatric populations. Philadelphia , ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... While a significant number of women and men with eating disorders report a ... that best predicts the development of an eating disorder. , At the ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... excited to share this important news! AHCC and the Home Health and Hospice ... Clinic, CMS' designee for official ICD coding guidance and clarifications, to address concerns ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is ... this country. The AutismOne 2016 Conference, which is being held May 25-29 at the ... hear elsewhere about helpful interventions and causes of chronic illness in children. , Very ...
(Date:2/7/2016)... Dallas, Texas (PRWEB) , ... February 07, 2016 ... ... its new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and ... , MyDecision™ combines three elements to cut the cost of providing employee healthcare ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. By manipulating each pixel, LUT's can change each color ...
Breaking Medicine News(10 mins):